News AZ's Alexion plans hit a snag as Ultomiris flunks ALS trial It has only been a month since AstraZeneca's $39 billion takeover of Alexion was completed, but the new combination has already had a setback.
News EHA21: Novartis trumpets iptacopan as oral alternative to an... The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option afte
Events Partner Content 3rd Annual Complement-based Drug Development Summit 2019 November 13-15, 2019 | Boston, MA
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.